Tenax Therapeutics (TENX) Projected to Post Quarterly Earnings on Wednesday

Tenax Therapeutics (NASDAQ:TENX) is expected to be posting its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect Tenax Therapeutics to post earnings of ($1.33) per share for the quarter. Individuals may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Wednesday, November 19, 2025 at 7:00 AM ET.

Tenax Therapeutics (NASDAQ:TENX) last issued its quarterly earnings results on Wednesday, August 13th. The specialty pharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.23. On average, analysts expect Tenax Therapeutics to post $-1 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Tenax Therapeutics Stock Up 1.6%

Tenax Therapeutics stock opened at $7.03 on Monday. The business’s 50-day simple moving average is $6.89 and its 200 day simple moving average is $6.26. The stock has a market cap of $32.08 million, a price-to-earnings ratio of -7.64 and a beta of 1.52. Tenax Therapeutics has a 12-month low of $4.50 and a 12-month high of $8.24.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on TENX. Piper Sandler started coverage on shares of Tenax Therapeutics in a research note on Monday, September 8th. They issued an “overweight” rating and a $20.00 target price on the stock. Guggenheim cut their price objective on shares of Tenax Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, August 14th. Wall Street Zen raised shares of Tenax Therapeutics to a “sell” rating in a research note on Saturday, October 25th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tenax Therapeutics in a report on Tuesday, October 14th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.